

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10522642
	Filing Date		2005-09-01
	First Named Inventor	Michael C. Van Zandt	
	Art Unit	1626	
	Examiner Name	Susannah Lee Chung	
	Attorney Docket Number	02-195-C9	

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	3557142		1971-01-19	Bell	
	2	4251528		1981-02-17	Brittain et al.	
	3	4283539		1981-08-11	Schnur	
	4	4438126		1984-03-20	Ueda et al.	
	5	4868301		1989-09-19	Mylari et al.	
	6	4939140		1990-07-03	Larson et al.	
	7	5064852		1991-11-12	Howard, Jr. et al.	
	8	5236945		1993-08-17	Mylari et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522642
Filing Date		2005-09-01
First Named Inventor	Michael C. Van Zandt	
Art Unit	1626	
Examiner Name	Susannah Lee Chung	
Attorney Docket Number	02-195-C9	

	9	5304557		1994-04-19	Mylari	
	10	5312829		1994-05-17	Okada et al.	
	11	5330997		1994-07-19	Mylari et al.	
	12	5332755		1994-07-26	Butler et al.	
	13	5641800		1997-06-24	Bach et al.	
	14	5700819		1997-12-23	Aotsuka et al.	
	15	5744488		1998-04-28	Cross et al.	
	16	6214991		2001-04-10	Jones et al.	
	17	6426344		2002-07-30	Jones et al.	
	18	7105514		2006-09-12	Jones et al.	
	19	6730794		2004-05-04	Jones et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10522642
Filing Date	2005-09-01
First Named Inventor	Michael C. Van Zandt
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	02-195-C9

20	7304079	2007-12-04	Jones et al.	
----	---------	------------	--------------	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20020161025		2002-10-31	Lebaut et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² ;	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	EP 0199543	EP		1986-10-29	ICI Americas Inc.		<input type="checkbox"/>
	2	EP 0539117	EP		1993-04-28	Lilly Industries Limited		<input type="checkbox"/>
	3	WO 96/03376	WO		1996-02-08	Eli Lilly		<input type="checkbox"/>
	4	EP 0054417	EP		1982-06-23	Pfizer Ltd.		<input type="checkbox"/>
	5	WO 95/06046	WO		1995-03-02	Pfizer Ltd.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10522642
Filing Date		2005-09-01
First Named Inventor	Michael C. Van Zandt	
Art Unit	1626	
Examiner Name	Susannah Lee Chung	
Attorney Docket Number	02-195-C9	

6	WO 93/12786	WO		1993-07-08	Harry Howard Jr.		<input type="checkbox"/>
7	EP 0222576	EP		1987-05-20	Pfizer		<input type="checkbox"/>
8	FR 2647676	FR		1990-12-07	Union Pharma Scient Appl.	Translated Abstract	<input type="checkbox"/>
9	EP 0401981	EP		1990-12-12	Pfizer		<input type="checkbox"/>
10	EP 0714893	EP		1996-06-05	Grelan Pharmaceutical Co.		<input type="checkbox"/>
11	WO 96/26207	WO		1996-08-29	Nissan Chemical Ind. Ltd.		<input type="checkbox"/>
12	JP7242628	JP		1995-09-19	Taisho Pharma Co. Ltd.	Translated Abstract	<input type="checkbox"/>
13	JP4244061	JP		1992-09-01	Fujisawa Pharmaceutical Co.	Translated Abstract	<input type="checkbox"/>
14	JP6041071	JP		1994-02-15	Taisho Pharma Co Ltd.	Translated Abstract	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS

Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10522642
Filing Date	2005-09-01
First Named Inventor	Michael C. Van Zandt
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	02-195-C9

1	Bach et al., "1H-Indole-1-Functional sPLA2 Inhibitors and Their Pharmaceutical Compositions and Use", Chemical Abstracts, Vol. 125, No. 10615, 1996.	<input type="checkbox"/>
2	Cross, Peter E. et al., "Selective Thromboxane Synthetase Inhibitors. 2. 3-(1H-Imidazol-1-Ylmethyl)-2-Methyl-1H-Indole-1-Propanoic Acid and Analogues", American Chemical Society, pp. 342-346 (1986)	<input type="checkbox"/>
3	Doebel, Karl J. et al., "Derivatives of Indole-1-Acetic Acid as Antiinflammatory Agents", Journal of Medicinal Chemistry, Vol. 15, No. 10, pp. 1081-1082 (1972).	<input type="checkbox"/>
4	Kador, Peter F. et al., "Aldose Reductase Inhibitors: A Potential New Class of Agents for the Pharmacological Control of Certain Diabetic Complications", Journal of Medicinal Chemistry (American Chemical Society), Vol. 28, No. 7, pp. 841-849 (1985).	<input type="checkbox"/>
5	Kador, Peter F. et al., "Pharmacophor Requirements of the Aldose Reductase Inhibitor Site", Molecular Pharmacology, Vol. 24, pp. 521-531 (1983).	<input type="checkbox"/>
6	Aotsuka, Tomoji et al., "Benzothiazol-2-Ylcarboxylic Acids with Diverse Spacers: A Novel Class of Potent, Orally Active Aldose Reductase Inhibitors", Biorganic & Medicinal Chemistry Letters, Vol. 7, No. 13, pp. 1677-1682 (1997).	<input type="checkbox"/>
7	Humber, Ph.D., Leslie, "The Medicinal Chemistry of Aldose Reductase Inhibitors, Chapter 5", Aldose Reductase Inhibition (Biomedical Information Corporation), pp. 326-353 (1987).	<input type="checkbox"/>
8	Larson, Eric R. et al., "Medicinal Chemistry of Aldose Reductase Inhibitors", Medicinal Research Reviews, Vol. 8, No. 2, pp. 159-186 (1988).	<input type="checkbox"/>
9	Dvornik, Dushan, "Inhibitors of Aldo Reductase, Chapter 16", Design of Enzyme Inhibitors as Drugs, Vol. 2, pp. 710-738, (1994).	<input type="checkbox"/>
10	Matassa, Victor G. et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3,5-Substituted Indoles and Indazoles", J. Med. Chem., Vol. 33, pp. 1781-1790 (1990).	<input type="checkbox"/>
11	Mylar, Banavara L. et al., "Novel, Potent Aldose Reductase Inhibitors: 3,4-Dihydro-4-Oxo-3-[[5-(Trifluoromethyl)-2-Benzothiazolyl]Methyl]-1-Phthalazine-Acetic Acid (Zopolrestat) and Congeners", J. Med. Chem., Vol. 34, No. 1, pp. 108-122 (1991).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10522642
Filing Date	2005-09-01
First Named Inventor	Michael C. Van Zandt
Art Unit	1626
Examiner Name	Susannah Lee Chung
Attorney Docket Number	02-195-C9

12	Aotsuka, Tomoji et al., "Novel and Potent Aldose Reductase Inhibitors: 4-Benzyl- and 4-(Benzothiazol-2-Ylmethyl)-3,4-Dihydro-3-Oxo-2 H-1,4-Benzothiazine-2-Acetic Acid Derivatives", Chem. Pharm. Bull., Vol. 42, No. 6, pp. 1264-1271 (1994).	<input type="checkbox"/>
13	Whitehead, C.W. et al., "Effect of Lipophilic Substituents on Some Biological Properties of Indoles" Journal of Medicinal Chemistry, Vol. 17, No. 12, pp. 1298-1304 (1974)	<input type="checkbox"/>
14	Dickinson, R.P. et al., "Thromboxane Modulating Agents. 2. Thromboxane Receptor Antagonists Derived from the Thromboxane Synthase Inhibitor Dazmegrel" Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 14, pp. 1691-1696, (1996).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.